- Home
- HLVX vs SGMO Comparison
HLVX vs SGMO Comparison
Compare HLVX & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- SGMO
- Stock Information
- Founded
- HLVX 2020
- SGMO 1995
- Country
- HLVX United States
- SGMO United States
- Employees
- HLVX N/A
- SGMO N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HLVX Health Care
- SGMO Health Care
- Exchange
- HLVX Nasdaq
- SGMO Nasdaq
- Market Cap
- HLVX 104.3M
- SGMO 122.8M
- IPO Year
- HLVX 2022
- SGMO 2000
- Fundamental
- Price
- HLVX $2.08
- SGMO $0.58
- Analyst Decision
- HLVX Hold
- SGMO Buy
- Analyst Count
- HLVX 1
- SGMO 6
- Target Price
- HLVX $2.00
- SGMO $4.50
- AVG Volume (30 Days)
- HLVX 829.7K
- SGMO 7.8M
- Earning Date
- HLVX 08-06-2025
- SGMO 08-07-2025
- Dividend Yield
- HLVX N/A
- SGMO N/A
- EPS Growth
- HLVX N/A
- SGMO N/A
- EPS
- HLVX N/A
- SGMO N/A
- Revenue
- HLVX N/A
- SGMO $81,706,000.00
- Revenue This Year
- HLVX N/A
- SGMO $1.29
- Revenue Next Year
- HLVX N/A
- SGMO $1.60
- P/E Ratio
- HLVX N/A
- SGMO N/A
- Revenue Growth
- HLVX N/A
- SGMO 565.52
- 52 Week Low
- HLVX $1.34
- SGMO $0.41
- 52 Week High
- HLVX $2.17
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- HLVX 52.92
- SGMO 58.57
- Support Level
- HLVX $2.07
- SGMO $0.50
- Resistance Level
- HLVX $2.10
- SGMO $0.58
- Average True Range (ATR)
- HLVX 0.04
- SGMO 0.05
- MACD
- HLVX -0.01
- SGMO 0.00
- Stochastic Oscillator
- HLVX 50.00
- SGMO 84.21
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.